CYTK insider buying and SEC filings, explained
Cytokinetics Inc. · CIK 1061983
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$4.7M
Planned sales (10b5-1)
$47.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Nov 2, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $62.81 ($471K), marked as a 10b5-1 plan trade. Holdings down 3% to 278,544 shares. | SEC filing Filed Nov 2, 2026, 6:18 PM ET |
| Oct 20, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $64.01 ($224K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Oct 20, 2026, 4:21 PM ET |
| Oct 12, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $62.88 ($472K), marked as a 10b5-1 plan trade. Holdings down 3% to 278,544 shares. | SEC filing Filed Oct 13, 2026, 4:00 PM ET |
| Oct 6, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $61.38 ($215K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Oct 6, 2026, 4:25 PM ET |
| Sep 28, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $65.46 ($491K), marked as a 10b5-1 plan trade. Holdings down 3% to 278,544 shares. | SEC filing Filed Sep 28, 2026 |
| Sep 22, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $68.29 ($239K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Sep 22, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Robert E Landry (Director) sold 1,000 shares at $72.13 ($72K), marked as a 10b5-1 plan trade. Holdings down 11% to 8,184 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 14–15, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 105,426 shares directly and indirectly (by trust) between Sep 14 and Sep 15 at about $69.62 ($7.3M), marked as a 10b5-1 plan trade. Direct holdings down 2% to 377,820 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 11, 2026 | Planned (10b5-1) | Robert E Landry (Director) sold 1,000 shares at $74.66 ($75K), marked as a 10b5-1 plan trade. Holdings down 10% to 9,184 shares. | SEC filing Filed Sep 11, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $75.46 ($264K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Sep 8, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | B. Lynne Parshall (Director) sold 5,000 shares at $71.48 ($357K), marked as a 10b5-1 plan trade. Holdings down 32% to 10,784 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 31, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 10,000 shares at $70.24 ($702K), marked as a 10b5-1 plan trade. Holdings down 15% to 58,555 shares. | SEC filing Filed Aug 31, 2026 |
| Aug 31, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $70.24 ($527K), marked as a 10b5-1 plan trade. Holdings down 2% to 377,820 shares. | SEC filing Filed Aug 31, 2026 |
| Aug 18, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $75.82 ($265K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Aug 18, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $76.76 ($576K), marked as a 10b5-1 plan trade. Holdings down 2% to 377,820 shares. | SEC filing Filed Aug 10, 2026 |
| Jul 30, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 14,000 shares at $79.88 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 19% to 58,555 shares. | SEC filing Filed Jul 30, 2026 |
| Jul 27, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $80.87 ($607K), marked as a 10b5-1 plan trade. Holdings down 2% to 377,820 shares. | SEC filing Filed Jul 27, 2026 |
| Jul 21, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $80.59 ($282K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Jul 23, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $82.02 ($615K), marked as a 10b5-1 plan trade. Holdings down 2% to 377,820 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $86.62 ($303K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $84.92 ($637K), marked as a 10b5-1 plan trade. Holdings down 2% to 377,830 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 15,000 shares at $85.80 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 20% to 58,555 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Sung Lee (CFO) sold 1,112 shares at $87.79 ($98K), marked as a 10b5-1 plan trade. Holdings down 2% to 63,221 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Sung Lee (CFO) sold 3,134 shares at $85.00 ($266K), marked as a 10b5-1 plan trade. Holdings down 5% to 63,221 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 24, 2026 | Planned (10b5-1) | Sung Lee (CFO) sold 38,730 shares at $82.30 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 38% to 63,221 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 23, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $79.51 ($278K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $70.46 ($528K), marked as a 10b5-1 plan trade. Holdings down 2% to 385,330 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 9, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $67.98 ($238K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Jun 9, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Edward M. MD Kaye (Director) sold 2,933 shares at $76.09 ($223K), marked as a 10b5-1 plan trade. Holdings down 22% to 10,283 shares. | SEC filing Filed Jun 1, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 15,000 shares at $74.08 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 20% to 58,555 shares. | SEC filing Filed Jun 1, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | B. Lynne Parshall (Director) sold 5,000 shares at $74.08 ($370K), marked as a 10b5-1 plan trade. Holdings down 24% to 15,784 shares. | SEC filing Filed Jun 1, 2026 |
| May 27, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $77.21 ($579K), marked as a 10b5-1 plan trade. Holdings down 2% to 392,830 shares. | SEC filing Filed May 28, 2026 |
| May 19, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $75.69 ($265K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed May 20, 2026 |
| May 14, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $77.92 ($584K), marked as a 10b5-1 plan trade. Holdings down 2% to 400,330 shares. | SEC filing Filed May 14, 2026 |
| May 5, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $77.37 ($271K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed May 5, 2026 |
| May 5, 2026 | Planned (10b5-1) | Wendell Wierenga (Director) sold 4,032 shares at $75.00 ($302K), marked as a 10b5-1 plan trade. Holdings down 11% to 32,637 shares. | SEC filing Filed May 5, 2026 |
| May 5, 2026 | Planned (10b5-1) | Sung Lee (CFO) sold 23,906 shares at $76.87 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 27% to 63,221 shares. | SEC filing Filed May 5, 2026 |
| May 5, 2026 | Planned (10b5-1) | John T. Henderson (Director) sold 20,000 shares at $75.97 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 21% to 75,237 shares. | SEC filing Filed May 5, 2026 |
| May 5, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 11,333 shares at $77.25 ($875K), marked as a 10b5-1 plan trade. Holdings down 16% to 58,555 shares. | SEC filing Filed May 5, 2026 |
| May 1, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 15,857 shares at $65.00 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 21% to 58,555 shares. | SEC filing Filed May 4, 2026 |
| Apr 30, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 15,000 shares at $63.26 ($949K), marked as a 10b5-1 plan trade. Holdings down 20% to 58,555 shares. | SEC filing Filed Apr 30, 2026 |
| Apr 29, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $59.62 ($447K), marked as a 10b5-1 plan trade. Holdings down 2% to 407,830 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 21, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares at $65.69 ($230K), marked as a 10b5-1 plan trade. Holdings down 2% to 153,902 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 7,449 shares at $66.02 ($492K), marked as a 10b5-1 plan trade. Holdings down 11% to 58,555 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $65.38 ($490K), marked as a 10b5-1 plan trade. Holdings down 2% to 415,330 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 7, 2026 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 4,500 shares at about $65.11 ($293K), marked as a 10b5-1 plan trade. Holdings down 3% to 153,902 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Robert I Blum (CEO and Director) sold 7,500 shares at $66.63 ($500K), marked as a 10b5-1 plan trade. Holdings down 2% to 422,830 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 31, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 3,639 shares at $65.00 ($237K), marked as a 10b5-1 plan trade. Holdings down 5% to 66,004 shares. | SEC filing Filed Mar 31, 2026 |
| Mar 18, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 1,930 shares at $62.07 ($120K), marked as a 10b5-1 plan trade. Holdings down 2% to 78,185 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 17, 2026 | Sale | Sung Lee (CFO) sold 4,935 shares at $62.15 ($307K). Holdings down 5% to 87,127 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 17, 2026 | Sale | Andrew Callos (EVP, Chief Commercial Officer) sold 8,542 shares at $62.15 ($531K). Holdings down 11% to 71,573 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 17, 2026 | Sale | Fady Ibraham Malik (EVP Research & Development) sold 12,033 shares at $62.15 ($748K). Holdings down 7% to 153,902 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 17, 2026 | Sale | Robert I Blum (CEO and Director) sold 36,601 shares at $62.15 ($2.3M). Holdings down 8% to 430,330 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 1,709 shares at $61.03 ($104K), marked as a 10b5-1 plan trade. Holdings down 4% to 46,149 shares. | SEC filing Filed Mar 16, 2026 |
| Mar 9, 2026 | Sale | Andrew Callos (EVP, Chief Commercial Officer) sold 2,582 shares at $60.72 ($157K). Holdings down 5% to 47,858 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Mar 9, 2026 | Sale | Fady Ibraham Malik (EVP Research & Development) sold 2,907 shares at $60.72 ($177K). Holdings down 2% to 138,629 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Mar 9, 2026 | Sale | Robert I Blum (CEO and Director) sold 7,931 shares at $60.72 ($482K). Holdings down 2% to 391,673 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 26,000 shares at about $61.87 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 34% to 50,440 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | B. Lynne Parshall (Director) sold 5,000 shares at $61.21 ($306K), marked as a 10b5-1 plan trade. Holdings down 22% to 17,933 shares. | SEC filing Filed Mar 2, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 886 shares at $61.62 ($55K), marked as a 10b5-1 plan trade. Holdings down 2% to 50,440 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 5, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 15,000 shares at $61.93 ($929K), marked as a 10b5-1 plan trade. Holdings down 23% to 50,440 shares. | SEC filing Filed Feb 5, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 886 shares at $62.10 ($55K), marked as a 10b5-1 plan trade. Holdings down 2% to 50,440 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 15,000 shares at $60.28 ($904K), marked as a 10b5-1 plan trade. Holdings down 23% to 50,440 shares. | SEC filing Filed Jan 5, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 1,798 shares at about $62.62 ($113K), marked as a 10b5-1 plan trade. Holdings down 3% to 50,440 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 29, 2025 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 1,809 shares at $62.44 ($113K), marked as a 10b5-1 plan trade. Holdings down 3% to 51,353 shares. | SEC filing Filed Dec 30, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Wendell Wierenga (Director) sold 20,000 shares at $66.14 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 38% to 32,444 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 2,200 shares at $61.24 ($135K), marked as a 10b5-1 plan trade. Holdings down 2% to 138,552 shares. | SEC filing Filed Dec 16, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 1,042 shares at $65.96 ($69K), marked as a 10b5-1 plan trade. Holdings down 2% to 50,660 shares. | SEC filing Filed Dec 8, 2025 |
| Dec 5, 2025 | Planned (10b5-1) | Andrew Callos (EVP, Chief Commercial Officer) sold 52,486 shares at $65.95 ($3.5M), marked as a 10b5-1 plan trade. Holdings down 51% to 50,660 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 2, 2025 | Planned (10b5-1) | John T. Henderson (Director) sold 8,750 shares at $63.90 ($559K), marked as a 10b5-1 plan trade. Holdings down 11% to 74,578 shares. | SEC filing Filed Dec 2, 2025 |
| Dec 2, 2025 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 2,200 shares at $63.89 ($141K), marked as a 10b5-1 plan trade. Holdings down 2% to 140,610 shares. | SEC filing Filed Dec 2, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Edward M. MD Kaye (Director) sold 28,064 shares at $66.72 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 74% to 9,977 shares. | SEC filing Filed Dec 2, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Robert Arthur Harrington (Director) sold 2,150 shares at $66.80 ($144K), marked as a 10b5-1 plan trade. Holdings down 10% to 18,542 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 19, 2025 | Planned (10b5-1) | B. Lynne Parshall (Director) sold 5,000 shares at $64.73 ($324K), marked as a 10b5-1 plan trade. Holdings down 18% to 22,933 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 18, 2025 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 2,200 shares at $66.45 ($146K), marked as a 10b5-1 plan trade. Holdings down 2% to 140,610 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 11, 2025 | Planned (10b5-1) | Edward M. MD Kaye (Director) sold 5,175 shares at $65.08 ($337K), marked as a 10b5-1 plan trade. Holdings down 34% to 9,977 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Fady Ibraham Malik (EVP Research & Development) sold 2,295 shares at $59.55 ($137K), marked as a 10b5-1 plan trade. Holdings down 2% to 140,610 shares. | SEC filing Filed Nov 4, 2025 |
98 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CYTK in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.